Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lucid Diagnostics (LUCD)
NASDAQ:LUCD
Lucid Diagnostics (LUCD) Stock Price & Analysis
217 Followers
LUCD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.76 - $1.85
Previous Close$0.8
Volume118.26K
Average Volume (3M)161.97K
Market Cap
$38.43M
Enterprise Value$12.68M
Total Cash (Recent Filing)$39.52M
Total Debt (Recent Filing)$13.78M
Price to Earnings (P/E)-0.6
Beta1.35
Next Earnings
May 08, 2024EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding48,244,798
10 Day Avg. Volume163,319
30 Day Avg. Volume161,971
Standard Deviation0.19
R-Squared0.21
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)4.61
Price to Sales (P/S)101.93
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue20.00
Enterprise Value/Gross Profit33.64
Enterprise Value/Ebitda-0.22
Forecast
1Y Price Target
$3.83Price Target Upside380.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Lucid Diagnostics News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLucid has shown strong revenue growth with EsoGuard tests increasing 137% year-over-year and revenue up 930% year-over-year.
Market OpportunityLucid Diagnostics Inc.'s target testing population is estimated to be between 25M-31M with a total addressable market of $48.5B-$60B, indicating a significant opportunity for growth.
Product EndorsementTwo leading gastroenterology specialty associations now support Lucid's EsoCheck Cell Collection Device and EsoGuard Esophageal DNA Test as an acceptable alternative to endoscopy.
Bears Say
Competitor's Product LimitationCompetitor Exact Sciences reported lower sensitivity in their Oncoguard test for detecting short segment Barrett's esophagus, which is a limitation for its use in widespread screening.
Financial PerformanceLUCD missed consensus revenue in 4Q23.
Product DemandEsoGuard test volume declined 15% sequentially in 4Q23.
---
Ownership Overview
67.86% Insiders
1.52% Mutual Funds
1.21% Other Institutional Investors
29.42% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
LUCD FAQ
What was Lucid Diagnostics’s price range in the past 12 months?
Lucid Diagnostics lowest stock price was $0.76 and its highest was $1.85 in the past 12 months.
What is Lucid Diagnostics’s market cap?
Currently, no data Available
When is Lucid Diagnostics’s upcoming earnings report date?
Lucid Diagnostics’s upcoming earnings report date is May 08, 2024 which is in 12 days.
How were Lucid Diagnostics’s earnings last quarter?
Lucid Diagnostics released its earnings results on Mar 25, 2024. The company reported -$1.33 earnings per share for the quarter, missing the consensus estimate of -$0.23 by -$1.1.
Is Lucid Diagnostics overvalued?
According to Wall Street analysts Lucid Diagnostics’s price is currently Undervalued.
Does Lucid Diagnostics pay dividends?
Lucid Diagnostics does not currently pay dividends.
What is Lucid Diagnostics’s EPS estimate?
Lucid Diagnostics’s EPS estimate is -$0.23.
How many shares outstanding does Lucid Diagnostics have?
Lucid Diagnostics has 48,244,797 shares outstanding.
What happened to Lucid Diagnostics’s price movement after its last earnings report?
Lucid Diagnostics reported an EPS of -$1.33 in its last earnings report, missing expectations of -$0.23. Following the earnings report the stock price went down -6.604%.
Which hedge fund is a major shareholder of Lucid Diagnostics?
Currently, no hedge funds are holding shares in LUCD
---
Lucid Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.83 (380.85% Upside)
$3.83 (380.85% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.25%
12-Months-Change
Fundamentals
Return on Equity
-507.97%
Trailing 12-Months
Asset Growth
-16.12%
Trailing 12-Months
Company Description
Lucid Diagnostics
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
---
LUCD Earnings Call
Q4 2024
0:00 / 0:00
---
LUCD Stock 12 Months Forecast
Average Price Target
$3.83
▲(380.85% Upside)
Technical Analysis
Best Analysts Covering LUCD
1 Year
1 Year Success Rate
1/15 ratings generated profit
1 Year Average Return
-40.91%
reiterated a buy rating 16 days ago
Copying Michael Matson's trades and holding each position for 1 Year would result in 6.67% of your transactions generating a profit, with an average return of -40.91% per trade.
---